

A double-blind, placebo-controlled trial of methylphenidate in children with hyperkinetic disorder and moderate-severe learning disabilities

Submission date 10/03/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 09/05/2006	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 16/01/2014	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Emily Simonoff

Contact details

Professor of Child and Adolescent Psychiatry
Child and Adolescent Psychiatry
Institute of Psychiatry
De Crespigny Park
London
United Kingdom
SE5 8AF
+44 (0)20 7848 5312
e.simonoff@iop.kcl.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

CT2004-1

Study information

Scientific Title

Acronym

HSEN

Study objectives

1. What is the efficacy of methylphenidate, under conditions of individual dose optimization, in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) among children with moderate and severe learning disabilities?
2. What is the adverse effects profile associated with methylphenidate treatment amongst children with learning disabilities and which children are at greater risk of developing side effects?
3. What are the predictors of good versus poor responders to treatment? In particular:
 - a. Are those with severe as opposed to moderate learning disabilities less likely to show a good response?
 - b. Presence of autistic symptoms

Ethics approval required

Old ethics approval format

Ethics approval(s)

South East Multicentre Research Ethics Committee: MREC 04/01/013

Study design

Randomized controlled trial stratified for severity of learning disability (30-49 versus 50-69).

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Hyperkinetic disorder, mental retardation (intellectual disability)

Interventions

180 children between ages 7 and 15 years with moderate-severe learning disability and hyperkinetic disorder will be invited to take part in a randomized double-blind trial of methylphenidate versus placebo lasting 16 weeks. Medication dosage for methylphenidate will be individually optimized, balancing reduction in hyperkinetic symptoms against side effects. Three dose levels of immediate release medication will be tried, corresponding to 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg daily dose in three divided doses (with the three doses corresponding to 40% in the morning, 40% at lunchtime and 20% after school of the total daily dose). Selection of optimal dose will be based on adverse effects and behavioural response. Treatment response will be determined by comparing baseline behaviour with that at 16 weeks. At the end of the 16 weeks, children will be unblinded. Those receiving placebo will have the opportunity to commence active medication with the same dose titration method. Those receiving active medication may continue in an open-label trial, with the possibility of an increase in dose up to 2.0 mg/kg if warranted based on adverse effects and behavioural response. The trial will end at 50 weeks post randomization. Primary outcome points are 16 and 50 weeks, with additional measures wherever possible at 8, 12, 26 and 38 weeks. Ascertainment of research subjects occurs via two arms: clinical referral and population screening.

Not part of treatment trial but interventions:

A behavioural manual (written by the team) is given to all families at the time of eligibility assessment.

Where children have sleep problems, their parents are given a manual on managing sleep problems (standard manual written by Paul Montgomery).

Where sleep problems are ongoing, children may be given melatonin, commencing with 4 mg dose and continuing in weekly 3 mg increments up to 8 mg.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Methylphenidate

Primary outcome measure

Conners parent and teacher questionnaires, short form: ADHD and hyperactivity indices

Secondary outcome measures

1. Adverse events (other behaviours questionnaire plus any others noted)
2. Aberrant behaviour questionnaire
3. Quality of Life (Cadfield)
4. Parental Report on Neuropsychiatric Symptoms (PONS)

Overall study start date

01/06/2004

Completion date

31/05/2007

Eligibility

Key inclusion criteria

1. Diagnosis of International Statistical Classification of Diseases and Related Health Problems - tenth revision (ICD-10) hyperkinetic disorder
2. Full-scale IQ 30-69 or age equivalent estimate
3. Living in catchment area of one of the participating centres
4. Child in stable care situation
5. Child regularly attending school (more than 75% of last school term)

Participant type(s)

Patient

Age group

Child

Sex

Both

Target number of participants

180

Key exclusion criteria

1. Child currently in another trial of psychoactive medication
2. Household member with recent diagnosis of substance abuse
3. Severe limitation of child's mobility
4. Presence of a degenerative disorder
5. Medical conditions precluding methylphenidate as treatment of first choice, including:
 - a. Poorly controlled or uncontrolled epilepsy
 - b. Presence of tics or Tourette disorder
 - c. History of psychotic, bipolar or severe obsessive compulsive disorder
 - d. Child on neuroleptic medication (must be withdrawn for 2 months prior to trial assessment)
 - e. History of intolerance to stimulant medication
 - f. Child poses a significant risk of suicidal or homicidal behaviour
6. Another child in the family/household already enrolled in this study
7. Ongoing child protection concerns

Date of first enrolment

01/06/2004

Date of final enrolment

31/05/2007

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Professor of Child and Adolescent Psychiatry
London
United Kingdom
SE5 8AF

Sponsor information

Organisation

King's College London (UK)

Sponsor details

Institute of Psychiatry
De Crespigny Park
London
England
United Kingdom
SE5 8AF
g.dale@iop.kcl.ac.uk

Sponsor type

University/education

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Charity

Funder Name

The Health Foundation

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2013		Yes	No